NanoVibronix, Inc. engages in the development of noninvasive biological response-activating devices. The company is headquartered in Tyler, Texas and currently employs 15 full-time employees. The company went IPO on 2015-04-24. The firm focuses on two distinct technology platforms: Acoustic-based therapeutic technologies, including PainShield and UroShield, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms. UroShield is an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters. The ENvue Navigation Platform, which is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract. ENvue provides real-time bedside visualization of tube movement and supports informed decision-making during the placement procedure.
Leveraging in-depth analyst evaluations, we have synthesized key insights from expert assessments to present a positive outlook for NAOV. Analysts highlight solid fundamentals and favorable market sentiment, suggesting upside potential in the near term. Based on this thorough expert analysis, we maintain an optimistic view of this stock. Our conclusion: NAOV is a Buy candidate.
NAOV stock price ended at $1.1 on 星期五, after dropping 5.17%
On the latest trading day Jan 23, 2026, the stock price of NAOV fell by 5.17%, dropping from $1.16 to $1.10. During the session, the stock saw a volatility of 7.27%, with prices oscillating between a daily low of $1.10 and a high of $1.18. On the latest trading day, the trading volume for NAOV decreased by 64.5K shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, 348.3K shares were traded, with a market value of approximately $1.1M.